INTRODUCTION {#s1}
============

Basal cell carcinoma (BCC) is the most common human cancer with an estimate of well over one million new cases diagnosed in the United States every year \[[@R1]\]. There are two main types of BCC: the less-aggressive (nodular and superficial) and the aggressive (infiltrative/morphea-like types). The morbidity from local invasion and destruction of the surrounding tissue can cause severe functional deficit and cosmetic disfigurement. However, it rarely metastasizes or causes death \[[@R2]\].

The sonic hedgehog (SHH) pathway is associated with BCC development \[[@R3]\]. This pathway is highly conserved across species, and it is responsible for controlling embryonic development and adult tissue homeostasis \[[@R4]\]. SHH binds to protein patched homolog 1 (PTCH1) and prevents PTCH1 from inhibiting smoothened (SMO). PTCH1 inhibits SMO from translocating to the cell membrane, thereby enhancing degradation of SMO. In the absence of PTCH1, the GLI-family proteins, key transcription factors downstream of SMO, thereby turn on SHH-responsive genes, including many prosurvival and other transcription factors that are essential for tumour growth and survival \[[@R5]\].

Mutations in PTCH1 can cause the development of nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome \[[@R6]\]. NBCCS is a predisposition to large numbers of BCCs. NBCCS patients have an inherited mutations at least one allele of the *PTCH1* gene \[[@R6]\]. In sporadic BCC patients, it is also estimated that loss of function mutations in *PTCH1* occur in 30-40%, while gain of function mutations in *SMO* are found in approximately 10% \[[@R7], [@R8]\]. Both mutations result in constitutive activation of SMO.

Treatment for BCC is largely achieved by surgical excision or destruction, but there are select cases of locally aggressive BCC where surgery may be complicated by severe functional compromise. Other therapeutic options include vismodegib, a recently FDA-approved SMO inhibitor for treating advanced BCC patients, or immune activation with imiquimod. These options, however, are not effective for all BCC patients. Imiquimod can only be used in superficial BCC \[[@R9]\]. It is also discouraging that objective responses of vismodegib were only seen in 30% of patients with metastatic BCC \[[@R10]\] and 43% \[[@R10]\] or 58% \[[@R11]\] of patients with locally advanced BCC. Therefore, further research in molecular mechanisms of BCC development are needed, in order to develop better therapies.

Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase of the insulin receptor superfamily \[[@R12]\]. It plays an important role in brain and neuronal development during embryogenesis. The expression of ALK is diminished in the adult; however, it is still found in specific tissues of neuronal origin. ALK is activated by its ligands, midkine (MDK) and pleiotrophin (PTN), both of which serve as mitogenic and angiogenic factors in cancer \[[@R13], [@R14]\]. ALK was initially identified as an oncogenic driver in anaplastic large cell lymphoma \[[@R15], [@R16]\]. Chromosomal translocations, resulting in fusion oncogene of ALK have also been described in multiple cancers such as non-small cell lung cancer, inflammatory myofibroblastic tumours, and others \[[@R17]-[@R20]\]. Furthermore, a number of gain of function point mutations in ALK have been identified in neuroblastoma \[[@R21]\], pointing to the important role of ALK in driving tumour development. An ALK inhibitor, crizotinib, has been recently FDA approved as a therapy for late stage non-small cell lung cancer with little side effects \[[@R22], [@R23]\]. This makes ALK an intriguing target as a therapy for many other cancers.

In this study, laser capture microdissection (LCM) was performed in combination with cDNA microarray analysis in order to discover molecular pathways that distinguish BCC from normal epidermal keratinocytes. We found that ALK was up-regulated by \>250 fold in BCC nodules and cognate activation of PTN and MDK ligands also occurred. ALK was phosphorylated in BCC tumour nests. Crizotinib reduced keratinocyte proliferation in culture in part by suppressing the expression of SHH signaling genes GLI1 and CCND2. Our data suggest that ALK activates GLI1 in parallel with the conventional SHH-pathway. Furthermore, ALK inhibitor alone or in combination with targeting the SHH-pathway molecules may be applicable for treating BCC patients.

RESULTS {#s2}
=======

Laser capture microdissection confirms previously identified genes using bulk tissue extracts from BCC tissue {#s2_1}
-------------------------------------------------------------------------------------------------------------

Laser capture microdissection was performed on both localized and infiltrative BCC (Figure [1A-F](#F1){ref-type="fig"}), followed by RNA extraction, target amplification and labeling, and hybridization onto Affymetrix HGU133A2.0 chips. In humans, BCC arises from the interfollicular epidermis; hence gene expression profiles of both BCC types were compared to those of microdissected epidermis from healthy volunteers. Table [1](#T1){ref-type="table"} shows selected up- and down-regulated genes among differentially expressed genes (false discovery rate \[FDR\]\<0.05, fold change \[FCH\]\>3.0). Many up-regulated genes in this short list confirm the results from previous microarray studies of BCC. Many keratinocyte differentiation marker genes (KRT2, FLG, LOR, LCE2B, and CDSN) were found to be down-regulated, but they were not detected in previous gene expression studies \[[@R24]-[@R26]\]. This may be explained by contamination of the normal epidermis within bulk tissue, thus showing the specificity of our LCM method to detect cancer cell specific gene expression changes. Six up- and down-regulated genes (genes with an asterisk in Table [1](#T1){ref-type="table"}) were further tested for their mRNA expression changes by quantitative RT-PCR (qRT-PCR). All genes were confirmed to be differentially expressed (*p*\< 0.05, Figure [1G-H](#F1){ref-type="fig"}), except for KLK11 expression in localized BCC, which failed to reach statistical significance. These findings showed a high correlation between FCH estimated by both methods (Pearson\'s r=0.96 and Spearman\'s ρ=0.86, *p*\<0.0001 for both, Figure [1I](#F1){ref-type="fig"}). These data support the consistency of our LCM derived gene sets with previous studies using bulk tissue extracts, and the accuracy of our gene sets.

![Laser capture microdissection identifies genes specific to BCC tumour nests](oncotarget-04-2237-g001){#F1}

###### Selected up- and down-regulated genes in laser captured BCC vs. laser captured normal epidermis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A. Selected up-regulated genes                                                                                                    
  ---------------------------------- ------------------ ------------- ------------------------------------------------------------- -------------------------------------
  CHGA\*                             206.08             823.37        chromogranin A                                                O\'Driscoll et al. 2006 \[[@R24]\]

  LGR5\*                             175.01             727.07        leucine-rich repeat-containing G protein-coupled receptor 5   O\'Driscoll et al. 2006 \[[@R24]\]\
                                                                                                                                    Tanese et al. 2008 \[[@R25]\]

  VCAN\*                             149.71             461.04        versican                                                      O\'Driscoll et al. 2006 \[[@R24]\]

  ADAMTS3\*                          136.08             420.00        ADAM metallopeptidase with thrombospondin type 1 motif, 3     O\'Driscoll et al. 2006 \[[@R24]\]\
                                                                                                                                    Tanese et al. 2008 \[[@R25]\]

  KRT17\*                            130.24             162.35        keratin 17                                                    Yu et al. 2008 \[[@R26]\]

  SOX11                              7.06               10.15         SRY (sex determining region Y)-box 11                         Tanese et al. 2008 \[[@R25]\]

  ALK\*                              249.46             1015.62       anaplastic lymphoma receptor tyrosine kinase                  O\'Driscoll et al. 2006 \[[@R24]\]

  PTN                                46.91              35.30         pleiotrophin                                                  N.R.

  MDK                                19.91              20.39         midkine                                                       N.R.

  B. Selected down-regulated genes                                                                                                  

  Gene symbol                        Fold change        Description   Reference                                                     

  Localized BCC                      Infiltrative BCC                                                                               

  KRT2\*                             2880.29            4104.53       keratin 2                                                     N.R.

  FLG                                989.12             2247.34       filaggrin                                                     N.R.

  LOR                                887.74             1354.93       loricrin                                                      N.R.

  SCEL\*                             210.40             633.85        sciellin                                                      N.R.

  ARG1\*                             412.71             337.79        arginase, liver                                               N.R.

  AZGP1\*                            237.04             297.35        alpha-2-glycoprotein 1, zinc-binding                          O\'Driscoll et al. 2006 \[[@R24]\]

  LCE2B                              230.72             219.18        late cornified envelope 2B                                    N.R.

  KLK11\*                            172.69             181.27        kallikrein-related peptidase 11                               N.R.

  HAL                                197.68             174.25        histidine ammonia-lyase                                       N.R.

  CDSN\*                             191.61             162.69        corneodesmosin                                                N.R.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

A false discovery rate \<10^−4^ is applied to all genes listed.

Genes with an asterisk were further confirmed by qRT-PCR method and the results were found in Figure [1G and 1H](#F1){ref-type="fig"}.

N.R.: Genes with no report in the previous BCC cDNA microarray studies.

ALK is overexpressed and phosphorylated in BCC tissue {#s2_2}
-----------------------------------------------------

ALK was found to be among the top 3 up-regulated genes for both types of BCCs with an approximately 250-FCH in localized BCC, and an approximately 1000-FCH in infiltrative BCC compared to microdissected normal human epidermis (FDR\<10^−4^, Table [1A](#T1){ref-type="table"}). Overexpression of ALK in microdissected BCC tissue was confirmed by qRT-PCR (Figure [1G](#F1){ref-type="fig"}). In order to obtain a broad view of the expression of ALK in skin diseases, qRT-PCR using total RNA extracted from bulk tissues was carried out. ALK expression was compared between different hyperproliferative skin diseases, such as psoriasis vulgaris and squamous cell carcinoma (SCC). There was a significantly higher expression of ALK in BCC compared to normal skin, psoriasis, and SCC (*p*\<0.05, Figure [2A](#F2){ref-type="fig"}). The phosphorylation status of ALK was evaluated in BCC, as well as in SCC and normal skin. Positive cytoplasmic staining of phosphorylated ALK (pALK) in all tumour nests in BCC was found (Figure [2B](#F2){ref-type="fig"}). It was noted that it also stained the basal layer of keratinocytes in normal skin (Figure [2C](#F2){ref-type="fig"}) and peripheral regions of the SCC tumour nests (Figure [2D](#F2){ref-type="fig"}).

![ALK and its ligands PTN and MDK are expressed in BCC tissue](oncotarget-04-2237-g002){#F2}

ALK ligands, MDK and PTN, are up-regulated in BCC {#s2_3}
-------------------------------------------------

MDK and PTN, the two known ligands that bind to ALK, were significantly up-regulated in BCC on our gene list (FCH\>20 and FCH\>35, respectively, Table [1A](#T1){ref-type="table"}). MDK and PTN were stained in BCC tissues by immunohistochemistry (IHC). MDK was found in cells within the tumour nests (Figure [2E](#F2){ref-type="fig"}), but there was no staining in normal skin (Figure [2F](#F2){ref-type="fig"}). PTN was present in cells at the periphery of the tumour nests (Figure [2G-H](#F2){ref-type="fig"}), confirming the presence of both ligands within the BCC microenvironment at the protein level. Cells responsible for the expression of PTN were then examined by double immunofluorescence (IF), showing colocalized CD68 and PTN staining; this demonstrates that CD68 positive myeloid lineage cells are producing PTN in BCC (Figure [2I](#F2){ref-type="fig"}).

ALK expression is associated with active tumour growth *in vivo* {#s2_4}
----------------------------------------------------------------

The IHC results suggest that ALK might be phosphorylated in proliferating keratinocytes. In addition, the prominent expression of Ki67, a proliferation marker, in human BCC tumour nests demonstrates the highly proliferative nature of this cancer (Figure [3A](#F3){ref-type="fig"}). Double IF staining using antibodies for pALK and Ki67 on human BCC tissues was carried out. There was positive nuclear staining of Ki67 and cytoplasmic staining of ALK within the same tumour nests (Figure [3B](#F3){ref-type="fig"}). This suggests a function of ALK in tumour proliferation in human BCC.

![ALK and GLI1 are expressed in highly proliferating keratinocytic tumours in human and mice](oncotarget-04-2237-g003){#F3}

Giuriato et al. \[[@R27]\] have developed mice transduced with NPM-ALK or TPM3-ALK fusion genes. These mice develop skin tumours as well as lymphoma. The skin tumours show follicular differentiation as evidenced by the lack of granular layer, the existence of clear cells, and architectural similarities of tumour compartments to the hair shaft (Figure [3C](#F3){ref-type="fig"}). These mouse tumours are highly proliferative as evidenced by PCNA staining (Figure [3D](#F3){ref-type="fig"}). As expected, ALK was positive in these tumours (Figure [3E-F](#F3){ref-type="fig"}). GLI1 expression was also examined as the SHH-pathway is known to be involved in hair follicle morphogenesis. As shown in Figure [3G](#F3){ref-type="fig"}, GLI1 expression at the peripheral area of the tumour nests was increased compared to normal epidermis (Figure [3H](#F3){ref-type="fig"}). Overall, these results associate the expression of ALK and GLI1 with keratinocyte proliferation.

ALK inhibitor inhibits normal keratinocyte proliferation *in vitro* {#s2_5}
-------------------------------------------------------------------

Crizotinib (PF-2341066, an ALK-inhibitor) is an FDA-approved drug for treating non-small cell lung cancer patients with a mutation in ALK. Since there are no commercially available BCC cell lines to date, the potential to inhibit proliferation of keratinocytes with crizotinib was evaluated using cultured normal human epidermal keratinocytes (NHEKs). The phosphorylation status of ALK in cultured keratinocytes was first evaluated by using flow cytometry analysis. ALK was consistently phosphorylated in all three NHEKs tested (Figure [4A](#F4){ref-type="fig"}). The mean of the median fluorescence intensity (MFI) was 1089, which was higher compared to the isotype control antibody with a mean MFI of 284. Cells were then cultured with or without crizotinib or a c-Met inhibitor (PF-04217403) in media with full supplements. The c-Met inhibitor at different doses was also included, as it is known that crizotinib can also inhibit c-Met activity. The number of keratinocytes in culture treated with crizotinib for 5 days was significantly lower than control (full media). A greater than 90% inhibition was observed after treatment with crizotinib at both doses (Figure [4B](#F4){ref-type="fig"}, *p*\<0.01). The c-Met inhibitor alone did not affect keratinocyte growth (Figure [4B](#F4){ref-type="fig"} and [4C-G](#F4){ref-type="fig"}). This further supports the role of ALK in regulating proliferation of keratinocytes.

![Crizotinib inhibits the growth of normal human epidermal keratinocytes](oncotarget-04-2237-g004){#F4}

ALK inhibitor represses the SHH-pathway in cultured keratinocytes {#s2_6}
-----------------------------------------------------------------

It has been reported that ALK induces GLI1 mRNA expression via PI3/Akt in a lymphoma cell line \[[@R28]\]. To further elucidate possible underlying mechanisms of the growth inhibition of cultured keratinocytes by crizotinib (an ALK inhibitor), mRNA expression of the SHH-pathway genes was evaluated after 24 and 48 hour treatment with indicated inhibitors and PBS as a control. The expression of each gene for each condition was normalized to that of control (PBS alone). The expression of GLI1 was significantly down-regulated in the cells after 24 hour treatment with 1000ng/ml of crizotinib (*p*\<0.05, Figure [5A](#F5){ref-type="fig"}) and it was further suppressed after 48 hours with 500 ng/ml and 1000ng/ml of crizotinib (*p*\<0.0001, Figure [5B](#F5){ref-type="fig"}). This suppression after 48 hour treatment with 1000ng/ml of crizotinib was obvious with an approximately 60% reduction compared to PBS. The expression of PTCH1 did not change after 24 hour culture with any treatment tested, whereas it was reduced after 48 hour culture with 500ng/ml and 1000ng/ml of crizotinib (*p*\<0.01, Figure [5C-D](#F5){ref-type="fig"}). The expression of CCND2 was significantly down-regulated by 1000ng/ml of crizotinib after 48 hours (*p*\<0.01, Figure [5F](#F5){ref-type="fig"}). This was also observed even in the cells after 24 hour culture with 500ng/ml and 1000ng/ml of crizotinib (*p*\<0.01, Figure [5E](#F5){ref-type="fig"}). There was a dose dependent manner of the effect of the crizotinib to reduce each gene expression.

![Crizotinib down-regulates the expression of the SHH-pathway genes in normal human epidermal keratinocytes](oncotarget-04-2237-g005){#F5}

The SHH-pathway genes are up-regulated in BCC tissue {#s2_7}
----------------------------------------------------

Finally, the expression of the SHH-pathway, known to be associated with BCC development, was evaluated in our nodular and infiltrative BCC transcriptomes. PTCH1, PTCH2, SMO, and key transcription factors of this pathway GLI1 and GLI2 were all up-regulated (Figure [6A](#F6){ref-type="fig"}). Up-regulation of four of these genes was further confirmed by qRT-PCR using the same LCM-derived RNA that we used for microarray analysis. SMO, PTCH1, GLI1, and GLI2 were all elevated in BCC compared to LCM normal epidermis (Figure [6B](#F6){ref-type="fig"}).

![The SHH-signaling genes were up-regulated in BCC tissue](oncotarget-04-2237-g006){#F6}

DISCUSSION {#s3}
==========

There is an increasing trend to treat specific cancers with cell-specific or pathway-specific antagonists \[[@R29]-[@R32]\]. In BCC, vismodegib has been recently approved by FDA for metastatic and locally advanced disease. This drug blocks the signaling from SMO to GLI1, resulting in the down-regulation of the SHH-pathway. It is well documented that the constitutive activation of the SHH-pathway, mainly due to loss of function mutations in PTCH1 or gain of function mutations in SMO, is present in the majority of NBCCS and sporadic BCC cases. However, results from first clinical trial of vismodegib were somewhat discouraging with a 30% response rate for metastatic and a 43% response rate for locally advanced BCC \[[@R10]\], followed by a report with a 58% response rate for locally advanced BCC \[[@R11]\]. In addition, drug resistance has been recently reported in 6 out of 20 locally advanced BCC patients during vismodegib treatment \[[@R33]\]. These data suggest that there may be alternative mechanisms that activate GLI1 in BCC. Another concern regarding the use of vismodegib is the fact that about 50% patients discontinued the drug due to its severe adverse effects \[[@R10], [@R34]\]. Thus, finding new therapeutic options for this cancer is essential.

In this study, we identified a new function of ALK in keratinocyte proliferation, as well as in activation of GLI1 signaling. The activation of GLI1 transcription factor by ALK was reported in a lymphoma cell line and was ascribed to signaling through PI3/Akt \[[@R28]\]. The function of ALK in keratinocytes has not been determined to date. This coordinate regulation of GLI1 expression by the conventional SHH-pathway and ALK is particularly interesting when put into the context of BCC biology. In fact, we found the overexpression of ALK mRNA in all 22 BCC cases studied. In a mouse model of BCC, it was suggested that the degree of expression of GLI1 or GLI2 has a critical impact on the development of BCC tumours \[[@R35]\]. In this regard, our data suggest that ALK may have a function in enhancing GLI1 expression in BCC in parallel to signaling through SMO activation. A proposed role of ALK in BCC is summarized in Figure [7](#F7){ref-type="fig"}.

![ALK may activate GLI1 in a coordinate fashion with the conventional SHH-pathway in BCC](oncotarget-04-2237-g007){#F7}

The feasibility of the use of ALK inhibitor in treating BCC is also supported by mouse models. There are mice transduced with NPM-ALK or TPM3-ALK fusion genes \[[@R27]\]. These mutations are known to lead to constitutive activation of ALK and are found in anaplastic lymphoma patients in humans \[[@R15], [@R16]\]. Thus, these mice were established as models of anaplastic lymphoma. Unexpectedly, these mice established keratinocytic tumours on their skin as well. While analyzing these skin lesions by H&E, we noticed the trichilemmal keratinization and strong expression of ALK and GLI1 within the tumours. These features in part overlap with BCC, which is often considered as a tumour with features of hair follicle differentiation \[[@R36]\]. Most importantly, these tumours were completely diminished when these mice were treated with crizotinib \[[@R27]\]. Taken together, our observations in both human BCC and mice suggest that ALK plays an important role in BCC growth, and therefore holds great potential as a therapeutic target for BCC.

The limitation of this study is a lack of direct evidence of the effect of ALK inhibitor on human BCC cells. However, it should be noted that there are no well established and fully characterized human BCC cell lines. Mouse models of BCC do not properly recapitulate human BCC. For example, some mice BCC model harbor mutations in GLI2 \[[@R37]\], which is very rarely seen in humans. The structure of mouse skin features follicular differentiation of keratinocytes; hence skin tumour pathology of the ALK transgene is a reflection of this differentiation bias in mouse skin.

In summary, an oncogene ALK was highly up-regulated in BCC. Our data suggest that ALK activates GLI1 in parallel with the conventional SHH-pathway and thus these distant surface molecules may cooperate or synergize in signal transduction. Given the fact that crizotinib is an already FDA approved drug, we believe that clinical trials using crizotinib alone or in combination with other therapies such as vismodegib are indicated.

MATERIALS AND METHODS {#s4}
=====================

The detailed protocols and statistical analysis are described in the supplemental materials and methods.

Patients and Samples {#s4_1}
--------------------

Institutional review board approval(Rockefeller University and Weill Cornell Medical University) and written informed consent were obtained before enrolling patients to participate in this study. The study was performed in adherence with the Declaration of Helsinki Principals. A total of 10 BCC samples were obtained during Mohs micrographic surgery.

LCM {#s4_2}
---

LCM was performed according to the manufacturer\'s protocol for the CellCut system (Molecular Machines and Industries).

RNA extraction {#s4_3}
--------------

Total RNA was extracted using RNeasy Micro Kit (QIAGEN).

cDNA microarray analysis {#s4_4}
------------------------

Target amplification and labeling was performed as reported previously \[[@R38]\]. Affymetrix HGU133A2.0 arrays were used. The data has been deposited at the Gene Expression Omnibus repository (GSE42109).

qRT-PCR {#s4_5}
-------

Standard TaqMan RT-PCR and pre-amplification RT-PCR methods (Applied Biosystems) were performed. All data were normalized to RPLP0/hARP. All primers and probes used in this study are listed in [Table S1](#SD1){ref-type="supplementary-material"}.

IHC and IF {#s4_6}
----------

Frozen skin sections were prepared and standard procedures were used. Slides of NPM-ALK and TPM3-ALK transgenic mice skin tumours were kindly provided by Dr. Fabienne Meggetto (INSERM, France). ALL antibodies used in this study are listed in [Table S2](#SD1){ref-type="supplementary-material"}.

Cell culture {#s4_7}
------------

NHEKs were purchased from PromoCell and cultured in the appropriate media. An ALK inhibitor (crizotinib, PF-2341066) and a c-Met inhibitor (PF-04217403) were purchased from Selleck.

Flow cytometry {#s4_8}
--------------

Suspensions of cultured NHEKs were stained according to standard procedures with anti-phospho ALK antibody or appropriate isotype control (Epitomics). Samples were acquired using the LSR II flow cytometer (BD Biosciences) and analyzed with Flowjo software (TreeStar Inc).

Statistical analysis {#s4_9}
--------------------

Microarray data was analyzed using R/Bioconductor packages. The Harshlight package \[[@R39]\] was used to scan Affymetrix chips for spatial artifacts. Expression values were obtained using the GCRMA-algorithm. Expression values were modeled using the mixed-effect framework of Bioconductor\'s *limma* package. Genes with FDR\<0.05 and FCH\>3.0 were considered as differentially expressed genes. Repeating measures ANOVA with adjusting p values using Dunnet\'s method was used to evaluate the results from RT-PCR. *P*\<0.05 was considered significant.

Supplementary materials and methods
===================================
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